Key result
MAPKAPK5-AS1, PXN-AS1, and URB1-AS1 lncRNAs show ~10-fold higher expression in non-functioning pituitary adenomas versus controls.
Why the study?
Long non-coding RNAs are dysregulated in various lesions including non-functioning pituitary adenomas, but the expression of specific lncRNAs in Iranian patients required assessment.
Case-Control
Effect estimate: Expression ratios 10, 11.22, and 9.33 (95% CI 3.94-25.36, 4.3-28.8, and 4.12-21.12)
p-value: p=< 0.0001
MAPKAPK5-AS1, PXN-AS1 and URB1-AS1 lncRNAs are upregulated in non-functioning pituitary adenomas and may play a role in their pathogenesis.
No immediate clinical implications for NFPA; hypothesis-generating for lncRNA roles in pathogenesis pending validation.
Long non-coding RNAs (lncRNAs) have been shown to be dysregulated in a variety of malignant and non-malignant lesions including non-functioning pituitary adenomas (NFPAs). In the current experimental study, we have selected six lncRNAs, namely MAPKAPK5-AS1, NUTM2B-AS1, ST7-AS1, LIFR-AS1, PXN-AS1 and URB1-AS1 to assess their expression in a cohort of Iranian patients with NFPA. MAPKAPK5-AS1, PXN-AS1 and URB1-AS1 were shown to be over-expressed in NFPA tissues compared with control samples (Expression ratios (95% CI) = 10 (3.94-25.36), 11.22 (4.3-28.8) and 9.33 (4.12-21.12); p values < 0.0001, respectively). The depicted ROC curves showed the AUC values of 0.73, 0.80 and 0.73 for MAPKAPK5-AS1, PXN-AS1 and URB1-AS1, respectively. Relative expression level of PXN-AS1 was associated with tumour subtype (p value = 0.49). Besides, relative expression levels of MAPKAPK5-AS1 and LIFR-AS1 were associated with gender of patients (p values = 0.043 and 0.01, respectively). Cumulatively, the current study indicates the possible role of MAPKAPK5-AS1, PXN-AS1 and URB1-AS1 lncRNAs in the pathogenesis of NFPAs.
No takes yet. Share an insight, caveat, or question.
Taheri et al. (2023) conducted a case-control in Non-functioning pituitary adenoma. MAPKAPK5-AS1, PXN-AS1 and URB1-AS1 lncRNAs vs. Control samples was evaluated on Expression levels of MAPKAPK5-AS1, PXN-AS1 and URB1-AS1 (Expression ratios 10, 11.22, and 9.33, 95% CI 3.94-25.36, 4.3-28.8, and 4.12-21.12, p=< 0.0001). MAPKAPK5-AS1, PXN-AS1 and URB1-AS1 lncRNAs were significantly over-expressed in non-functioning pituitary adenoma tissues compared with control samples (p<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: